post-marketing surveillance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Democratic Left's theoretical foundation was rooted in the "New Times" intellectual movement that had emerged within Marxism Today during the 1980s. This movement, led by figures such as Martin Jacques, Stuart Hall, and Eric Hobsbawm, argued that the late 1980s represented a fundamental break with previous history, transitioning from Fordism to Post-Fordism. The "New Times" theorists contended that workers in western nations were no longer concentrated in large workplaces but were increasingly employed in the service and public sectors, requiring new political strategies beyond traditional class-based approaches. The influence of these ideas extended far beyond the Communist Party. Hobsbawm served as an advisor to Neil Kinnock, while many members of Blair's inner circle were former Eurocommunists influenced by the "New Times" school. Stuart Hall's analysis of Thatcherism - a term he pioneered - was cited by Labour Party figures in discussions about political strategy and messaging.
He is very fashionable and idolizes Oscar Wilde and Magnus Bane. While he is usually kind, he is often drunk and holds an extreme grudge against Alastair Carstairs. He also considers himself a murderer after indirectly causing his mother, Charlotte, to have a miscarriage; he keeps this secret from most people, even his family and friends. Matthew has dark gold hair and green eyes; he is also bisexual. He has complicated feelings for Cordelia. Thomas Lightwood — James's friend, a gentle young man who recently returned from his travel year in Spain. Thomas used to be small and sickly and was often considered meek, though this changed after he had a growth spurt. He is considered the "one with the kind heart" in his friend group, though he does enjoy teasing his friends. Thomas is very tall (at 6'5, he is the tallest of the characters) with broad shoulders, sandy brown hair, and hazel eyes. He also has complicated feelings for Alastair Carstairs. Christopher Lightwood — James's friend and Thomas's cousin, an absent-minded young man with the mind of an inventor. He gets distracted easily, though he is intelligent and well-meaning. He is fond of experimenting, though many of his experiments end up going awry. Christopher has dark brown hair and eyes described as the color of lilacs; he usually wears thick glasses. Alastair Carstairs — Cordelia's stern older brother, who was in a secret relationship with Charles Fairchild for the majority of the book. He is grumpy and arrogant but holds a soft spot for Thomas and cares for Cordelia.
== History == Generate:Biomedicines was founded in 2018 by Flagship Pioneering. The company was established to develop a data-driven approach to understanding the relationship between protein sequence and function with the aim of creating novel proteins for therapeutic purposes. The company operated in stealth mode until its public unveiling on September 10, 2020. At that time, Generate announced its focus on using machine learning algorithms and big data to design biological compounds targeting multiple diseases, including SARS-CoV-2, the virus causing COVID-19. Its computational platform integrated vast datasets of protein structures and genetic sequences to develop governing rules for designing new proteins. In March 2021, Mike Nally, formerly of Merck, joined as chief executive officer to advance the company's technology and operational capabilities. Under his leadership, Generate expanded its infrastructure and initiated multiple strategic collaborations. By 2023, Generate had raised financing, including a $273 million Series C round, the largest biotech Series C of the year. These funds supported the company's first-in-human clinical trial for GB-0669, a monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein, and its pipeline of 17 programs spanning immunology, infectious disease, and oncology. In September 2024, Generate secured a partnership with Novartis, potentially worth over $1 billion, to leverage its generative artificial intelligence (AI) platform for the development of protein therapeutics.
Sources: en.wikipedia.org
Amorpha-4,11-diene 12-monooxygenase (EC 1.14.14.114, CYP71AV1) is an enzyme with systematic name amorpha-4,11-diene,NADPH:oxygen oxidoreductase (12-hydroxylating). This enzyme catalyses the following overall chemical reaction
Inherited deficiency of urocanase leads to elevated levels of urocanic acid in the urine, a condition known as urocanic aciduria. Urocanase is found in some bacteria (gene hutU), in the liver of many vertebrates and has also been found in the plant Trifolium repens (white clover). Urocanase is a protein of about 60 Kd, it binds tightly to NAD+ and uses it as an electrophil cofactor. A conserved cysteine has been found to be important for the catalytic mechanism and could be involved in the binding of the NAD+.
== See also == Alkali-metal thermal to electric converter – Electrochemical device to convert heat Atomic battery – Devices generating electricity from radioisotope decay Betavoltaics – Type of nuclear battery which generates electric currentPages displaying short descriptions of redirect targets Kilopower Reactor Using Stirling Technology – NASA project aimed at producing a nuclear reactor for spacePages displaying short descriptions of redirect targets Optoelectric nuclear battery – Electric battery using nuclear energy Radioisotope heater unit – Device that provides heat through radioactive decay Radioactive isotope – Atom that has excess nuclear energy, making it unstablePages displaying short descriptions of redirect targets Stirling Radioisotope Generator – Type of atomic batteryPages displaying short descriptions of redirect targets Thermionic converter – Power generation device
== Organizations == SST Inc. also known as ShotSpotter Inc. Silicon Storage Technology, Inc, former US semiconductor manufacturer School of Science and Technology, high school in Oregon, US School of Science and Technology, Singapore Special Security Team, a counter-terrorist unit of the Japanese Coast Guard
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.